Towards Healthcare
Cell And Gene Therapy Clinical Trials Market Grows at 15.43% CAGR till 2034

Cell And Gene Therapy Clinical Trials Market 2025 CRO Partnerships and AI Driving Next-Gen Therapeutics

Market insights predict the global cell and gene therapy clinical trials industry will increase from USD 10.8 billion in 2024 to USD 45.31 billion by 2034, achieving a CAGR of 15.43%. Advancements in technologies such as gene editing, CAR-T therapy, and CRISPR-Cas9 have enabled the healthcare sector to address and fulfill the unmet medical needs of patients. North America, especially the U.S., led the global market in 2024 owing to the high prevalence of targeted diseases and robust R&D infrastructure.

Content

  • Insight Code: 5967
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The cell and gene therapy clinical trials market is projected to reach USD 45.31 billion by 2034, growing at a CAGR of 15.43% from 2024 to 2034.

North America is currently leading the cell and gene therapy clinical trials market due to rising focus on personalized medicine and growing investment in developing therapies for rare disorders.

The cell and gene therapy clinical trials market includes five segments such as end user application setting, manufacturing modality, cell source, indication, and therapy type.

Bluebird Bio, Allogene Therapeutics, Beam Therapeutics, Krystal Biotech, etc., are the specialized biotechnology companies advancing in cell and gene therapy clinical trials in North America.

The future of gene and cell therapies is promising due to technological advancements to treat incurable diseases.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions